Table 1

Crude and adjusted proportions of emergency presentations (EPs)*, by sex, age group, deprivation quintile and cancer diagnosis, for patients diagnosed in 2006 and 2013

	2006				2013
	No. of EPs	No. of cancer cases	Crude %	Adjusted %	No. of EPs	No. of cancer cases	Crude %	Adjusted %
All cases	56 551	237 415	23.8	23.0	55 313	276 569	20.0	20.4
Sex
Female	26 418	117 696	22.4	23.4	25 907	135 095	19.2	20.8
Male	30 133	119 719	25.2	22.7	29 406	141 474	20.8	20.0
Age group (years)
25–49	3199	23 733	13.5	16.6	3345	27 644	12.1	16.0
50–59	5386	34 264	15.7	17.1	4961	37 537	13.2	15.5
60–69	10 479	57 421	18.2	18.2	10 414	72 393	14.4	15.4
70–79	16 995	67 896	25.0	22.6	15 285	76 869	19.9	18.9
80+	20 492	54 101	37.9	33.3	21 308	62 126	34.3	30.7
Deprivation
1 (least)	8744	46 474	18.8	19.9	9253	56 976	16.2	17.9
2	10 805	50 313	21.5	21.5	10 836	60 509	17.9	18.9
3	11 863	50 385	23.5	22.6	11 605	58 390	19.9	19.9
4	12 361	47 230	26.2	24.3	11 871	53 392	22.2	21.7
5 (most)	12 778	43 013	29.7	26.9	11 748	47 302	24.8	23.5
Cancer site
Melanoma	241	8699	2.8	3.3	237	12 120	2.0	2.3
Breast	1859	38 913	4.8	5.2	1739	44 738	3.9	4.4
Oral	135	1924	7.0	7.1	134	2624	5.1	5.8
Thyroid	137	1617	8.5	9.4	182	2640	6.9	7.7
Uterine	536	6040	8.9	9.4	538	7420	7.3	8.0
Ororpharyngeal	123	1274	9.7	10.4	131	2261	5.8	7.2
Testicular	156	1524	10.2	14.3	143	1709	8.4	12.0
Prostate	3345	31 803	10.5	10.4	3134	40 146	7.8	8.2
Cervical	273	2335	11.7	14.1	260	2572	10.1	11.4
Laryngeal	215	1763	12.2	11.6	186	1807	10.3	10.7
Anal	99	765	12.9	13.6	131	1012	12.9	13.2
Sarcoma	171	1077	15.9	16.5	168	1522	11.0	12.6
HL	168	1056	15.9	20.0	212	1285	16.5	19.0
Rectal	1815	11 217	16.2	15.5	1441	11 182	12.9	12.4
Bladder	1723	8491	20.3	17.0	1536	8716	17.6	15.4
Oesophageal	1489	6451	23.1	21.1	1433	7215	19.9	19.1
CLL	632	2482	25.5	23.8	481	2908	16.5	17.1
NHL	2274	8405	27.1	27.2	2843	11 118	25.6	25.5
Renal	1594	5774	27.6	27.4	1775	8338	21.3	23.0
Ovarian	1806	5787	31.2	32.9	1591	6069	26.2	27.6
Colon	6524	19 431	33.6	29.8	6625	22 328	29.7	26.7
Stomach	2134	6346	33.6	29.9	1849	5603	33.0	28.7
CML	189	536	35.3	35.2	167	597	28.0	29.3
Mesothelioma	745	2086	35.7	35.4	736	2247	32.8	30.5
Multiple myeloma	1307	3563	36.7	35.3	1473	4642	31.7	31.2
Lung	12 735	32 680	39.0	36.6	12 653	36 247	34.9	33.0
Liver	1334	2774	48.1	46.6	1845	4300	42.9	41.3
Small intestine	360	746	48.3	48.6	533	1185	45.0	44.7
Pancreatic	3387	6718	50.4	47.6	3482	7804	44.6	42.9
AML	1115	2091	53.3	50.8	1246	2389	52.2	51.1
ALL	121	215	56.3	59.6	146	253	57.7	61.5
CUP	5618	9453	59.4	54.0	4172	7646	54.6	49.6
Brain	2191	3379	64.8	69.2	2091	3926	53.3	59.2

*Adjusted proportions estimated from a multivariable logistic regression model where outcome is EP (vs non-EP), and independent variables are sex, age group, deprivation, cancer site, year, age group*year, deprivation*year and cancer site*year (year entered as continuous variable both for main and interaction terms). The adjusted proportion in a given year was the predicted proportion of EPs, had the distribution of case-mix variables in that particular year been the same as that observed across all study years (2006–2013).
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; CUP, cancer of unknown primary; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma.